Kalohexis Data Suggests Dual MC3R/MC4R Activation Could Drive Safer Weight Loss
Event summary
- Kalohexis presented data at ENDO 2026 showing its dual MC3R/MC4R agonist achieved 11.8% weight loss in obese nonhuman primates over 15 weeks with limited rebound.
- The treatment preserved lean mass and showed no cardiovascular safety risks, addressing historical concerns with MC4R-selective approaches.
- Kalohexis' oral dual MC3R/MC4R agonist, 710GO, is currently in a Phase 1 clinical trial for general obesity.
- The company was spun out of Endevica Bio in March 2026 and focuses on metabolic disease care.
The big picture
Kalohexis' approach of dual MC3R/MC4R activation represents a novel mechanism in the weight loss market, potentially offering a safer and more durable solution compared to existing therapies. The company's focus on leveraging the melanocortin system aligns with broader industry trends towards targeted metabolic interventions. Success in clinical trials could position Kalohexis as a key player in the obesity treatment space.
What we're watching
- Clinical Trial Progress
- How the Phase 1 trial of 710GO will proceed and whether it will demonstrate similar efficacy and safety in humans.
- Market Differentiation
- Whether Kalohexis can position 710GO as a safer and more effective alternative to existing weight loss treatments.
- Regulatory Pathway
- The pace at which Kalohexis can navigate regulatory approvals for 710GO and bring it to market.
Related topics